Recro Pharma Inc. (REPH)’s Financial Results Comparing With Sangamo Therapeutics Inc. (NASDAQ:SGMO)

As Biotechnology companies, Recro Pharma Inc. (NASDAQ:REPH) and Sangamo Therapeutics Inc. (NASDAQ:SGMO) are our subject to compare. And more specifically their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Recro Pharma Inc. 78.61M 2.36 62.51M -2.76 0.00
Sangamo Therapeutics Inc. 70.69M 13.04 62.76M -0.69 0.00

Table 1 demonstrates Recro Pharma Inc. and Sangamo Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the return on equity, net margins and return on assets of both companies.

Net Margins Return on Equity Return on Assets
Recro Pharma Inc. -79.52% -273.4% -34.7%
Sangamo Therapeutics Inc. -88.78% -22.1% -13.9%

Volatility and Risk

Recro Pharma Inc.’s current beta is -0.58 and it happens to be 158.00% less volatile than Standard and Poor’s 500. Sangamo Therapeutics Inc.’s 204.00% more volatile than Standard and Poor’s 500 which is a result of the 3.04 beta.

Liquidity

The Current Ratio of Recro Pharma Inc. is 1.4 while its Quick Ratio stands at 1.2. The Current Ratio of rival Sangamo Therapeutics Inc. is 6.3 and its Quick Ratio is has 6.3. Sangamo Therapeutics Inc. is better equipped to clear short and long-term obligations than Recro Pharma Inc.

Analyst Recommendations

The following table given below contains the ratings and recommendations for Recro Pharma Inc. and Sangamo Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Recro Pharma Inc. 0 0 1 3.00
Sangamo Therapeutics Inc. 0 2 0 2.00

Competitively the average price target of Sangamo Therapeutics Inc. is $11, which is potential 21.82% upside.

Institutional and Insider Ownership

Recro Pharma Inc. and Sangamo Therapeutics Inc. has shares owned by institutional investors as follows: 67.4% and 66.2%. Insiders owned 6.09% of Recro Pharma Inc. shares. Competitively, Sangamo Therapeutics Inc. has 0.1% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Recro Pharma Inc. 19.79% 7.96% 1.42% 47.65% -18.87% -14.92%
Sangamo Therapeutics Inc. -5.58% -18.32% -20.27% -25.37% -32.09% -28.78%

For the past year Recro Pharma Inc. was less bearish than Sangamo Therapeutics Inc.

Summary

Recro Pharma Inc. beats Sangamo Therapeutics Inc. on 6 of the 11 factors.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. Its lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. The company also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain. It also provides contract development and manufacturing services. It has a license agreement with Orion Corporation for the development and commercialization of Non-Injectable Dexmedetomidine. The company focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The companyÂ’s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in HuntingtonÂ’s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.